Stockscreener 앱 받기
0.5468
1.05%
0.0057
시간 외 거래:
.53
-0.0168
-3.07%
전일 마감가:
$0.5411
열려 있는:
$0.5429
하루 거래량:
478.83K
Relative Volume:
0.11
시가총액:
$14.51M
수익:
-
순이익/손실:
$-26.56M
주가수익비율:
-0.8412
EPS:
-0.65
순현금흐름:
$-22.29M
1주 성능:
-2.01%
1개월 성능:
+26.78%
6개월 성능:
-42.97%
1년 성능:
-59.68%
1일 변동 폭
$0.52
$0.56
1주일 범위
$0.4732
$0.56
52주 변동 폭
$0.34
$1.6196
BiomX Inc Stock (PHGE) Company Profile
명칭
BiomX Inc
전화
972 7 23942377
주소
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
PHGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.5468 | 13.66M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-15 | 개시 | Ladenburg Thalmann | Buy |
BiomX Inc 주식(PHGE)의 최신 뉴스
Published on: 2025-08-20 04:33:53 - classian.co.kr
BiomX announces U.S. FDA placed clinical hold on Phase 2b trial of BX004 - TipRanks
BiomX’s mid-stage cystic fibrosis trial put on clinical hold; Santen makes a deal with RemeGen - Endpoints News
Correction to BiomX Article - MarketScreener
BiomX Faces FDA Hold on Phase 2b Study - TipRanks
BiomX's BX004: A Phage Therapy Revolution in the Orphan Drug Market - AInvest
BiomX Inc. Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis - MarketScreener
BiomX Inc. Reports Q2 2025 Progress and Financials - MSN
Technical Models Suggest BiomX Inc. May Rebound SoonJuly 2025 Breakouts & High Accuracy Swing Entry Alerts - thegnnews.com
Does BiomX Inc. fit your quant trading modelQuarterly Profit Summary & Weekly Watchlist of Top Performers - Newser
Applying chart zones and confluence areas to BiomX Inc.Recession Risk & Scalable Portfolio Growth Ideas - Newser
What institutional flow reveals about BiomX Inc.July 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
Should you wait for a breakout in BiomX Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - Newser
Applying big data sentiment scoring on BiomX Inc.2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Earnings visualization tools for BiomX Inc.2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
What Fibonacci levels say about BiomX Inc. reboundPortfolio Growth Summary & Long-Term Investment Growth Plans - Newser
BiomX Inc. Stock Performance After Earnings: Historical InsightsJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Can trapped investors hope for a rebound in BiomX Inc.July 2025 Sector Moves & Stock Portfolio Risk Management - Newser
BiomX Inc. stock prediction for this weekShare Buyback & Step-by-Step Trade Execution Guides - Newser
How BiomX Inc. stock performs during market volatilityTrade Analysis Summary & AI Enhanced Market Trend Forecasts - Newser
Analyzing drawdowns of BiomX Inc. with statistical toolsShort Setup & Accurate Technical Buy Alerts - Newser
BiomX Inc. (AMEX:PHGE) Q2 2025 Earnings Call Transcript - Insider Monkey
BiomX Inc. shares fall 2.82% premarket after reporting second quarter 2025 financial results. - AInvest
BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study - MSN
BiomX Posts Q2 Loss With 14% Cost Drop - AOL.com
BiomX's Q2 2025 Earnings Call: Unraveling Contradictions in BX211 and BX004 Development Strategies - AInvest
Trend analysis for BiomX Inc. this weekJuly 2025 Sector Moves & Short-Term High Return Ideas - Newser
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Transcript : BiomX Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
BiomX Inc (PHGE) Reports Q2 2025 EPS of -$0.33, Net Loss of $6 M - GuruFocus
BiomX Reports Q2 GAAP EPS of -$0.19, Cash Balance Decreases to $15.2 Million - AInvest
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - TradingView
News impact scoring models applied to BiomX Inc.July 2025 News Drivers & Weekly Chart Analysis and Trade Guides - Newser
Technical Models Suggest BiomX Inc. May Rebound Soon [July 2025 Breakouts]Risk Managed Investment Entry Signals - 선데이타임즈
BiomX Announces Q2 2025 Financial Results and Initiates Phase 2B Trial for Cystic Fibrosis Treatment - AInvest
BiomX: Positioning Phage Therapy as a High-Probability, High-Impact Play in the Antibiotic Resistance Crisis - AInvest
How to escape a deep drawdown in BiomX Inc.Market Volume Summary & Reliable Momentum Entry Alerts - Newser
BiomX Earnings Preview: What to Expect on August 13th - AInvest
BiomX Inc.’s Price Action Aligns with Quant SignalsBreakout Confirmation With Entry Tracker Enabled - 선데이타임즈
What to Expect From BiomX's Earnings - 富途牛牛
Should I buy BiomX Inc. stock before earningsPredictive Analytics for Equity Growth Potential - Newser
Can BiomX Inc. hit a new high this monthIntraday Price Action Forecast Planner - Newser
Why BiomX Inc. is moving todayTrend Analysis for Safer Market Entries - Newser
BiomX (PHGE) Projected to Post Earnings on Wednesday - Defense World
BiomX Inc (PHGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):